Toripalimab to prevent cancer return after head and neck treatment
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial tests toripalimab (an immunotherapy drug) given as maintenance to help keep locally advanced head and neck squamous cell cancer from coming back after you have no remaining visible tumor. It may help the immune system stay alert and improve outcomes after standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have head and neck squamous cell cancer that was locally advanced (stage III–IV) and confirmed by pathology at the start of treatment.
- After your first treatment (surgery, radiation, chemotherapy, and/or targeted treatments), there must be no remaining tumor lesions.
- Your cancer must have “high-risk” features such as T3–4 stage, positive lymph nodes, tumor invading blood vessels or nerves, certain lymph node capsule involvement, or a positive surgical margin.
- You must be 18–70 years old and be able to do daily activities at a level score of 0 or 1 (called ECOG).
- There must be no spread to distant organs (no distant metastasis) on scans at enrollment.
- Your blood counts, liver/kidney tests, heart pumping strength (left ventricular ejection fraction ≥ 50%), blood clotting tests, and thyroid test (TSH ≤ 1.5 times normal) must fall within required limits. (You also must have no active bleeding or blood clot issues.)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immune checkpoint inhibitor (a drug that helps your immune system fight cancer) as maintenance therapy after chemoradiotherapy improves outcomes for people with locally advanced head and neck cancer. It specifically looks at a marker in your blood (CD8Tex cells) to see if you might benefit.
This trial studies toripalimab to lower the risk of the cancer coming back after surgery and additional chemo-radiation. It may help the immune system “finish the job” after your main treatment, especially if you have higher-risk features.
This trial tests toripalimab (an immunotherapy) given before surgery for untreated head and neck squamous cell carcinoma, either alone or with chemotherapy. The goal is to shrink or control the cancer earlier and see if it improves outcomes for people who plan curative surgery.
This trial looks at whether continuing immunotherapy can help keep cancer from coming back in people with head and neck cancer who had a good response to chemo-immunotherapy before surgery. You would have already had surgery, and now the study tests a maintenance treatment to strengthen your immune system's fight against any remaining cancer cells.
This trial tests whether adding an immunotherapy drug (toripalimab) with or without another targeted drug (cetuximab) to standard chemotherapy before surgery can improve outcomes for people with advanced head and neck squamous cell carcinoma that can be removed with surgery.
This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (cetuximab)—given before surgery to shrink advanced head and neck cancers. The goal is to see if this approach can lower the risk of the cancer coming back.
Hear when a new Locally Advanced Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.